CoChat

Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer’s Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Open access

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Abstract

BACKGROUND: LMTM is being developed as a treatment for AD based on inhibition of tau aggregation. OBJECTIVES: To examine the efficacy of LMTM as monotherapy in non-randomized cohort analyses as modified primary outcomes in an 18-month Phase III trial in mild AD. METHODS: Mild AD patients (n = 800) were randomly assigned to 100 mg twice a day or 4 mg twice a day. Prior to unblinding, the Statistical Analysis Plan was revised to compare the 100 mg twice a day as monotherapy subgroup (n = 79) versus 4 mg twice a day as randomized (n = 396), and 4 mg twice a day as monotherapy (n = 76) versus 4 mg twice a day as add-on therapy (n = 297), with strong control of family-wise type I error. RESULTS: The revised analyses were statistically significant at the required threshold of p < 0.025 in both comparisons for change in ADAS-cog, ADCS-ADL, MRI atrophy, and glucose uptake. The brain atrophy rate was initially typical of mild AD in both add-on and monotherapy groups, but after 9 months of treatment, the rate in monotherapy patients declined significantly to that reported for normal elderly controls. Differences in severity or diagnosis at baseline between monotherapy and add-on patients did not account for significant differences in favor of monotherapy. CONCLUSIONS: The results are consistent with earlier studies in supporting the hypothesis that LMTM might be effective as monotherapy and that 4 mg twice a day may serve as well as higher doses. A further suitably randomized trial is required to test this hypothesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-170560

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig.1 Trial profile.
Fig.1 Trial profile.CC BY · PubMed Central
Fig.2 Least squares estimates of mean change from baseline and S.E. on primary and principal secondary outcomes. Primary analyses as defined in the revised Statistical Analysis Plan compared 100 mg twice a day as monotherapy with all patients receiving 4 mg twice a day (control as randomly assigned; comparison A) and 4 mg twice a day as monotherapy with same dose as add-on to approved treatment for AD (comparison B). Comparison C, 100 mg twice a day as monotherapy with same dose as add-on to approved treatment for AD, is also shown.
Fig.2 Least squares estimates of mean change from baseline and S.E. on primary and principal secondary outcomes. Primary analyses as defined in the revised Statistical Analysis Plan compared 100 mg twice a day as monotherapy with all patients receiving 4 mg twice a day (control as randomly assigned; comparison A) and 4 mg twice a day as monotherapy with same dose as add-on to approved treatment for AD (comparison B). Comparison C, 100 mg twice a day as monotherapy with same dose as add-on to approved treatment for AD, is also shown.CC BY · PubMed Central
Fig.3 Least squares estimates of mean change from baseline and S.E. on MRI volumetric outcomes: lateral ventricular volume, whole brain volume and hippocampal volume. Comparisons shown are 100 mg twice a day as monotherapy with all patients receiving 4 mg twice a day (control as randomly assigned, Comparison A) and 4 mg twice a day as monotherapy with same dose as add-on to approved treatment for AD (Comparison B) and 100 mg twice a day as monotherapy with same dose as add-on to approved treatment for AD(Comparison C).
Fig.3 Least squares estimates of mean change from baseline and S.E. on MRI volumetric outcomes: lateral ventricular volume, whole brain volume and hippocampal volume. Comparisons shown are 100 mg twice a day as monotherapy with all patients receiving 4 mg twice a day (control as randomly assigned, Comparison A) and 4 mg twice a day as monotherapy with same dose as add-on to approved treatment for AD (Comparison B) and 100 mg twice a day as monotherapy with same dose as add-on to approved treatment for AD(Comparison C).CC BY · PubMed Central
Fig.4 Annualized rate of whole brain atrophy (expressed as %) over months 0–6 and months 12–18 in monotherapy patients. The rates are compared with those reported by Leung et al. for mild AD and normal elderly controls [20].
Fig.4 Annualized rate of whole brain atrophy (expressed as %) over months 0–6 and months 12–18 in monotherapy patients. The rates are compared with those reported by Leung et al. for mild AD and normal elderly controls [20].CC BY · PubMed Central
Fig.5 Voxel-based morphometric comparison showing regions of greater atrophy in patients receiving LMTM as monotherapy [N = 157] (A) or as add-on to approved treatments for AD [N = 610], (B) in TRx-237-005 compared with elderly controls [N = 244] from the ongoing Aberdeen birth cohort studies [23, 26], controlled for age, sex and total intracranial volume of each individual. (C) Voxel-based morphometric comparison of monotherapy and add-on patients in TRx-237-005. Data are displayed at a significance threshold corrected for family-wise error at the whole brain level at p < 0.05.
Fig.5 Voxel-based morphometric comparison showing regions of greater atrophy in patients receiving LMTM as monotherapy [N = 157] (A) or as add-on to approved treatments for AD [N = 610], (B) in TRx-237-005 compared with elderly controls [N = 244] from the ongoing Aberdeen birth cohort studies [23, 26], controlled for age, sex and total intracranial volume of each individual. (C) Voxel-based morphometric comparison of monotherapy and add-on patients in TRx-237-005. Data are displayed at a significance threshold corrected for family-wise error at the whole brain level at p < 0.05.CC BY · PubMed Central
Fig.6 A) Change from baseline at 9-month and 18-month time points for temporal cortex SUVR measured by 18F-FDG-PET normalized with respect to pons. B) Change from baseline at 9-month and 18-month time points for temporal cortex SUVR measured by 18F-FDG-PET normalized with respect to cerebellum.
Fig.6 A) Change from baseline at 9-month and 18-month time points for temporal cortex SUVR measured by 18F-FDG-PET normalized with respect to pons. B) Change from baseline at 9-month and 18-month time points for temporal cortex SUVR measured by 18F-FDG-PET normalized with respect to cerebellum.CC BY · PubMed Central
Fig.7 Relationship between decline on the ADAS-cog scale over 18 months and relative volume of nucleus basalis and nucleus accumbens normalized according to AD-comedication treatment status with cholinesterase inhibitors, memantine or LMTM as monotherapy. Mean (±SE) relative volume as a proportion of per-subject whole brain volume (× 10–4) of nucleus basalis (A1) and nucleus accumbens (B1) in 4 groups is shown according to increasing degree of atrophy. Illustrative relationship between decline on the ADAS-cog scale over 18 months and nucleus basalis relative atrophy group (A2–A4) and nucleus accumbens relative atrophy group (B2 –B4) in patients receiving LMTM in combination with an acetylcholinesterase inhibitor (A2 & B2), with memantine (A3 & B3) or as monotherapy (A4 & B4). Statistical relationships reported in the main text are for the overall significance of the term covariate x visit in explaining cognitive decline.
Fig.7 Relationship between decline on the ADAS-cog scale over 18 months and relative volume of nucleus basalis and nucleus accumbens normalized according to AD-comedication treatment status with cholinesterase inhibitors, memantine or LMTM as monotherapy. Mean (±SE) relative volume as a proportion of per-subject whole brain volume (× 10–4) of nucleus basalis (A1) and nucleus accumbens (B1) in 4 groups is shown according to increasing degree of atrophy. Illustrative relationship between decline on the ADAS-cog scale over 18 months and nucleus basalis relative atrophy group (A2–A4) and nucleus accumbens relative atrophy group (B2 –B4) in patients receiving LMTM in combination with an acetylcholinesterase inhibitor (A2 & B2), with memantine (A3 & B3) or as monotherapy (A4 & B4). Statistical relationships reported in the main text are for the overall significance of the term covariate x visit in explaining cognitive decline.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Wischik, 2017, J Alzheimers Dis
  2. Gharid A , Atamna H (2011) Methylene blue induces mitochondrial complex IV and improves cognitive function and grip strength in old mice. In Neurodegeneration: Theory, Disorders and Treatments, McNeill AS , ed. AS Nova Science Publishers, Hauppauge, NY, pp. 63–85.

Cited by

See all 221

Metadata

Authors
Wilcock, G. K., Gauthier, S., Frisoni, G. B., Jia, J., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Schelter, B. O., Wischik, D. J., Davis, C. S., Staff, R. T., Vuksanovic, V., Ahearn, T., Bracoud, L., Shamsi, K., Marek, K., Seibyl, J., Riedel, G., Storey, J. M. D., Harrington, C. R., & Wischik, C. M.
Affiliations
  • University of Oxford (GB)
  • Douglas Mental Health University Institute (CA)
  • University of Geneva (CH)
  • Beijing Institute for Brain Disorders (CN)
  • TauRx (United Kingdom) (GB)
  • Moebius-Consult, Baar, Switzerland
  • Birmingham and Solihull Mental Health NHS Foundation Trust (GB)
  • Salamandra LLC, Bethesda, MD, USA
  • University of Aberdeen (GB)
  • University of Cambridge (GB)
  • CSD Biostatistics, Tucson, AZ, USA
  • Aberdeen Biomedical Imaging Centre, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK
  • BioClinica, Lyon, France
  • RadMD, New York, NY, USA
  • MNI Imaging, New Haven, CT, USA
Corresponding author
Wischik, Claude M.
Venue
Journal of Alzheimer's Disease
Published
2017-11-28
Volume
61
Issue
1
Pages
435-457
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2768871557
Cited by
219
References
57
Citations by year
2026: 16 · 2025: 26 · 2024: 30 · 2023: 31 · 2022: 28 · 2021: 27 · 2020: 27 · 2019: 17 · 2018: 16 · 2017: 1
FWCI
12.55
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion)
  • Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Funders
  • TauRx Pharmaceuticals
  • European Commission
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
MeSH terms
Mental Status and Dementia Tests, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Female, Humans, International Cooperation, Male, Methylene Blue, Middle Aged, Antipsychotic Agents, Cohort Studies, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.